论文部分内容阅读
目的研究宫颈腺癌组织中精子相关抗原9(SPAG9)的表达及其临床应用价值。方法采用免疫组化链霉亲和素-生物素-过氧化物酶复合物技术(streptavidin biotin-peroxidase complex method,SABC)检测50例宫颈腺癌和18例正常宫颈组织中SPAG9蛋白的表达。结果 SPAG9在宫颈腺癌中的阳性表达率为100%,在正常宫颈组织中表达率为0。根据H-score值,不同病理分级宫颈腺癌中SPAG9表达比较,差异有统计学意义(t=0.661,P<0.05),但不同临床分期和盆腔淋巴结转移SPAG9表达比较,差异无统计学意义(t=0.705和1.874,P均>0.05)。低分化宫颈腺癌患者SPAG9蛋白的表达[(3.25±0.47)分]与高、中分化[(3.18±0.36)分]比较,差异有统计学意义(P<0.05)。有盆腔淋巴结转患者SPAG9蛋白的表达[(3.39±0.46)分]与无淋巴结转移[(3.18±0.29)分]比较,差异无统计学意义(P>0.05);Ⅱ~Ⅳ期宫颈腺癌患者SPAG9蛋白的表达[(3.43±0.42)分]与Ⅰ期[(3.07±0.35)分]比较,差异无统计学意义(P>0.05)。结论 SPAG9蛋白在宫颈腺癌组织中存在高表达,可能在宫颈腺癌的发生和发展中起重要作用,具有成为其协助诊断和判断预后的分子标志物和靶向治疗靶点的潜能。
Objective To study the expression of sperm-associated antigen 9 (SPAG9) in cervical adenocarcinoma and its clinical value. Methods SPAG9 protein was detected in 50 cases of cervical adenocarcinoma and 18 cases of normal cervical tissue by immunohistochemical streptavidin biotin-peroxidase complex method (SABC). Results The positive expression rate of SPAG9 in cervical adenocarcinoma was 100%, and it was 0 in normal cervical tissue. According to the H-score, the expression of SPAG9 in cervical adenocarcinoma with different histological grade was statistically different (t = 0.661, P <0.05), but there was no significant difference in SPAG9 expression between different clinical stages and pelvic lymph node metastasis t = 0.705 and 1.874, all P> 0.05). The expression of SPAG9 protein in patients with poorly differentiated cervical adenocarcinoma [(3.25 ± 0.47) score] was significantly higher than that in patients with high or moderate differentiation [(3.18 ± 0.36) score] (P <0.05). There was no significant difference in the expression of SPAG9 protein in patients with pelvic lymph node metastasis [(3.39 ± 0.46) points vs no lymph node metastasis (3.18 ± 0.29) points) (P> 0.05) There was no significant difference in the expression of SPAG9 [(3.43 ± 0.42) points vs [Ⅰ (3.07 ± 0.35) points] (P> 0.05). Conclusion SPAG9 protein is highly expressed in cervical adenocarcinoma and may play an important role in the development and progression of cervical adenocarcinoma. It has the potential to be a molecular marker and a target for targeted therapy in diagnosis and prognosis of cervical adenocarcinoma.